News & Updates

Show Multimedia Only

Abnormal nighttime BP doubles death risk in diabetes patients

14 Oct 2021 by

For adults with diabetes, increased blood pressure (BP) at night (reverse dipping) was associated with more than double the risk of death compared with those whose BP dipped as expected at night, according to the longitudinal CHAMP1ON study presented at Hypertension 2021.

14 Oct 2021

Second bDMARD after failure of non-TNFi biologic in RA shows modest drug survival, response

14 Oct 2021

A recent study has shown modest drug survival and primary response of a second biologic disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA) switching due to failure of a nontumour necrosis factor inhibitor (non-TNFi) bDMARD as the first agent.

14 Oct 2021

Smoking reduces effect of methotrexate-based treatment in RA patients

14 Oct 2021

Current smoking reduces the response of patients with early rheumatoid arthritis (RA) to methotrexate (MTX) in a dose-responsive manner, regardless of concomitant prednisone use, a recent study has found.

14 Oct 2021

Lenzilumab reduces likelihood of survival without ventilation in COVID-19 patients

14 Oct 2021 by

In hospitalized COVID-19 patients, treatment with the novel GM-CSF* neutralizing monoclonal antibody lenzilumab led to a significant improvement in survival without invasive mechanical ventilation (SWOV), findings from the phase III LIVE-AIR study suggest.

14 Oct 2021

Azithromycin not effective against peripartum infection in high-risk, labouring women

14 Oct 2021

A single dose of oral azithromycin with or without amoxicillin falls short of reducing the risk of maternal peripartum or neonatal infection among women experiencing prolonged labour or rupture of membranes at term, a study has found.

14 Oct 2021

Nirsevimab reduces RSV LRTIs in infants

14 Oct 2021 by

A single dose of nirsevimab significantly reduced the incidence of medically attended respiratory syncytial virus (RSV)-confirmed lower respiratory tract infections (LRTIs) in healthy infants during their first RSV season, according to the MELODY* study presented at IDWeek 2021.

14 Oct 2021

Common, cheap osteoporosis drug promising for T2D

14 Oct 2021 by

The osteoporosis drug alendronate halves the risk of developing type 2 diabetes (T2D) in a nationwide, retrospective, case-control study of nearly 700,000 patients from Denmark.

14 Oct 2021

Dapagliflozin improves symptoms, physical limitations in HFpEF

13 Oct 2021 by

Patients with heart failure and preserved ejection fraction (HFpEF) treated with dapagliflozin experienced improvements in symptoms and physical limitations, according to results of the PRESERVED-HF study presented at HFSA 2021.

13 Oct 2021

Cilostazol makes good in DAPT for recurrent stroke prevention in high-risk patients

13 Oct 2021 by

Dual antiplatelet therapy (DAPT) with cilostazol performs better than either aspirin or clopidogrel alone at reducing the risk of recurrent stroke or vascular events without increasing the incidence of bleeding for patients with ischaemic stroke and intracranial arterial stenosis, according to the results of the CSPS.com* trial.

13 Oct 2021

Older adults with atrophic gastritis, on high-dose PPI at risk of vitamin B-12 deficiency

13 Oct 2021 by

Indicators of vitamin B-12 deficiency are more likely to present among older adults with atrophic gastritis (AG) or those using higher doses of proton pump inhibitors (PPIs), suggests a study.

13 Oct 2021

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Abnormal nighttime BP doubles death risk in diabetes patients

Second bDMARD after failure of non-TNFi biologic in RA shows modest drug survival, response

Smoking reduces effect of methotrexate-based treatment in RA patients

Lenzilumab reduces likelihood of survival without ventilation in COVID-19 patients

Azithromycin not effective against peripartum infection in high-risk, labouring women

Nirsevimab reduces RSV LRTIs in infants

Common, cheap osteoporosis drug promising for T2D

Dapagliflozin improves symptoms, physical limitations in HFpEF

Cilostazol makes good in DAPT for recurrent stroke prevention in high-risk patients

Older adults with atrophic gastritis, on high-dose PPI at risk of vitamin B-12 deficiency